Abvc Biopharma Inc (ABVC)

$1.80 +0.03 (1.69%)
Market Cap 46.80M
Revenue (ttm) 0.00
Net Income (ttm) -7.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 118,800
Avg Vol 121,512
Day's Range N/A - N/A
Shares Out 26.00M
Stochastic %K 94%
Beta 0.54
Analysts Strong Buy
Price Target $20.20

Company Profile

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 668 0881
Address:
44370 Old Warm Springs Boulevard, Fremont, United States
BigdollarMaker
BigdollarMaker Jul. 2 at 7:01 PM
$BB $ABVC Then the rip$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 2 at 1:36 PM
$BB $ABVC When news hits, people don’t even realize how big this is.
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 1 at 8:00 PM
$BB $ABVC Green looks good on you $$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 1 at 5:48 PM
$ABVC $BB busting out
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 1 at 3:12 PM
$BB $ABVC Bring it$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 30 at 7:49 PM
$ABVC $BB More to come, big money incoming$$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 29 at 4:15 PM
$BB $ABVC Cheers$$$ We deserve it!!
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 29 at 3:54 PM
$ABVC $BB To the moon and beyond$$$$
0 · Reply
vcaelum
vcaelum Jun. 25 at 5:20 PM
$ABVC in 1.57 HARD SL 1.4
0 · Reply
BigBoyTroy
BigBoyTroy Jun. 24 at 10:41 PM
$ABVC come join me in free discord link in my stoctwits Profile my bullish 🐂 peeps ABVC levels Support Zones $1.20 – $1.25 → $1.05 – $1.15 → $0.90 – $1.00 → major support $0.70 – $0.80 : Resistance Zones $1.30 – $1.35 $1.45 – $1.55 $1.70 – $1.90 $2.00+
0 · Reply
Latest News on ABVC
ABVC BioPharma Quarterly report: Q1 2026

May 18, 2026, 7:00 AM EDT - 6 weeks ago

ABVC BioPharma Quarterly report: Q1 2026

ABVC BioPharma Proxy statement: Proxy Filing

Mar 5, 2026, 7:00 AM EST - 4 months ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Annual report: Q4 2025

Mar 3, 2026, 7:00 AM EST - 4 months ago

ABVC BioPharma Annual report: Q4 2025

ABVC BioPharma Proxy statement: Proxy Filing

Feb 5, 2026, 7:00 AM EST - 5 months ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Earnings release: Q3 2025

Nov 3, 2025, 7:30 AM EST - 8 months ago

ABVC BioPharma Earnings release: Q3 2025

ABVC BioPharma Quarterly report: Q3 2025

Nov 3, 2025, 7:30 AM EST - 8 months ago

ABVC BioPharma Quarterly report: Q3 2025

ABVC BioPharma Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

ABVC BioPharma Earnings release: Q2 2025

ABVC BioPharma Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

ABVC BioPharma Quarterly report: Q2 2025

ABVC BioPharma files $100M mixed securities shelf

2025-05-22T20:05:31.000Z - 1 year ago

ABVC BioPharma files $100M mixed securities shelf

ABVC BioPharma Registration statement: Registration Filing

May 22, 2025, 8:00 AM EDT - 1 year ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Quarterly report: Q1 2025

Apr 29, 2025, 6:00 PM EDT - 1 year ago

ABVC BioPharma Quarterly report: Q1 2025

ABVC BioPharma Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Earnings release: Q4 2024

Apr 15, 2025, 8:00 AM EDT - 1 year ago

ABVC BioPharma Earnings release: Q4 2024

ABVC BioPharma Quarterly report: Q4 2024

Apr 15, 2025, 8:00 AM EDT - 1 year ago

ABVC BioPharma Quarterly report: Q4 2024

ABVC BioPharma Annual report: Q4 2024

Apr 15, 2025, 8:00 AM EDT - 1 year ago

ABVC BioPharma Annual report: Q4 2024

ABVC BioPharma believes ABV-1504 can fill void in market after Prozac

2024-12-19T13:35:35.000Z - 1 year ago

ABVC BioPharma believes ABV-1504 can fill void in market after Prozac

ABVC BioPharma receives $200,000 cash payment from OncoX

2024-12-11T11:40:46.000Z - 1 year ago

ABVC BioPharma receives $200,000 cash payment from OncoX

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

Dec 11, 2024, 6:30 AM EST - 1 year ago

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year

2024-11-14T14:05:42.000Z - 1 year ago

ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year

ABVC BioPharma Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

ABVC BioPharma Quarterly report: Q3 2024

ABVC BioPharma Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

ABVC BioPharma Earnings release: Q3 2024

ABVC BioPharma receives $50,000 in incremental licensing fees

2024-10-22T12:50:33.000Z - 1 year ago

ABVC BioPharma receives $50,000 in incremental licensing fees

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Oct 22, 2024, 8:45 AM EDT - 1 year ago

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma Slides: Corporate Presentation

Aug 20, 2024, 7:00 AM EDT - 2 years ago

ABVC BioPharma Slides: Corporate Presentation

ABVC BioPharma reports Q2 EPS (9c) vs (68c) last year

2024-08-15T11:32:43.000Z - 2 years ago

ABVC BioPharma reports Q2 EPS (9c) vs (68c) last year

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Aug 15, 2024, 7:30 AM EDT - 2 years ago

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC BioPharma Quarterly report: Q2 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

ABVC BioPharma Quarterly report: Q2 2024

ABVC BioPharma Earnings release: Q2 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

ABVC BioPharma Earnings release: Q2 2024

ABVC BioPharma files to sell 1M shares of common stock for holders

2024-06-21T21:04:40.000Z - 2 years ago

ABVC BioPharma files to sell 1M shares of common stock for holders

ABVC BioPharma Registration statement: Registration Filing

Jun 21, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma’s AiBtl BioPharma acquires TT Life Company

2024-04-18T13:27:06.000Z - 2 years ago

ABVC BioPharma’s AiBtl BioPharma acquires TT Life Company

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Apr 18, 2024, 9:25 AM EDT - 2 years ago

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

ABVC BioPharma executes global licensing agreement for treatment of NSCLC

2024-04-17T13:07:50.000Z - 2 years ago

ABVC BioPharma executes global licensing agreement for treatment of NSCLC

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Apr 17, 2024, 9:00 AM EDT - 2 years ago

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Apr 10, 2024, 8:30 AM EDT - 2 years ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

ABVC BioPharma enters into global licensing deal with ForSeeCon Eye

2024-03-26T12:35:24.000Z - 2 years ago

ABVC BioPharma enters into global licensing deal with ForSeeCon Eye

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Mar 26, 2024, 8:30 AM EDT - 2 years ago

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma Proxy statement: Proxy Filing

Mar 25, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Registration statement: Registration Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Mar 19, 2024, 8:30 AM EDT - 2 years ago

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Mar 14, 2024, 9:30 AM EDT - 2 years ago

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

ABVC BioPharma Annual report: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Annual report: Q4 2023

ABVC BioPharma Earnings release: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Earnings release: Q4 2023

ABVC BioPharma Proxy statement: Proxy Filing

Mar 14, 2024, 8:00 AM EDT - 2 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma provides update on development of combination therapy

2024-02-27T13:43:29.000Z - 2 years ago

ABVC BioPharma provides update on development of combination therapy

ABVC BioPharma Registration statement: Registration Filing

Feb 16, 2024, 7:00 AM EST - 2 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Feb 15, 2024, 8:30 AM EST - 2 years ago

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

ABVC BioPharma receives Australian patent for treatment of MDD

2024-02-12T13:35:59.000Z - 2 years ago

ABVC BioPharma receives Australian patent for treatment of MDD

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Feb 12, 2024, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

ABVC BioPharma Registration statement: Registration Filing

Feb 9, 2024, 7:00 AM EST - 2 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma acquires $2.96M worth of land in Asia

2024-02-08T14:18:01.000Z - 2 years ago

ABVC BioPharma acquires $2.96M worth of land in Asia

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Feb 8, 2024, 9:17 AM EST - 2 years ago

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

ABVC BioPharma files to sell 10.4M shares of common stock for holders

2024-01-12T22:04:03.000Z - 2 years ago

ABVC BioPharma files to sell 10.4M shares of common stock for holders

ABVC BioPharma Registration statement: Registration Filing

Jan 12, 2024, 7:00 AM EST - 2 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma, BioLite receive $460M milestone payment from AiBtl

2024-01-03T12:27:54.000Z - 2 years ago

ABVC BioPharma, BioLite receive $460M milestone payment from AiBtl

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Jan 3, 2024, 7:24 AM EST - 2 years ago

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

ABVC BioPharma Proxy statement: Proxy Filing

Dec 29, 2023, 7:00 AM EST - 2 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Proxy statement: Proxy Filing

Dec 15, 2023, 7:00 AM EST - 2 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Dec 7, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Nov 21, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Nov 16, 2023, 10:05 AM EST - 2 years ago

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Nov 15, 2023, 9:00 AM EST - 2 years ago

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

ABVC BioPharma Quarterly report: Q3 2023

Nov 15, 2023, 7:00 AM EST - 2 years ago

ABVC BioPharma Quarterly report: Q3 2023

ABVC BioPharma Earnings release: Q3 2023

Nov 15, 2023, 7:00 AM EST - 2 years ago

ABVC BioPharma Earnings release: Q3 2023

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Oct 26, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Oct 17, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

Oct 9, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

Aug 23, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

ABVC Executes Cooperation Agreement for Strategic Investments

Aug 17, 2023, 9:19 AM EDT - 3 years ago

ABVC Executes Cooperation Agreement for Strategic Investments

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Aug 10, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

ABVC Corporate Update and CEO's Letter to Shareholders

Aug 7, 2023, 8:30 AM EDT - 3 years ago

ABVC Corporate Update and CEO's Letter to Shareholders

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

Aug 3, 2023, 9:20 AM EDT - 3 years ago

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

Aug 1, 2023, 8:30 AM EDT - 3 years ago

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

Jul 31, 2023, 9:30 AM EDT - 3 years ago

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

Jul 27, 2023, 9:22 AM EDT - 3 years ago

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

Jul 26, 2023, 8:30 AM EDT - 3 years ago

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

ABVC BioPharma Announces Reverse Stock Split

Jul 24, 2023, 12:30 PM EDT - 3 years ago

ABVC BioPharma Announces Reverse Stock Split

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

Jul 6, 2023, 8:30 AM EDT - 3 years ago

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

Jun 26, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

ABVC BioPharma Proxy statement: Proxy Filing

Jun 21, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

Jun 20, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Jun 12, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

ABVC BioPharma Registration statement: Registration Filing

Jun 8, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Registration statement: Registration Filing

Jun 7, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

Jun 6, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

ABVC BioPharma Registration statement: Registration Filing

Jun 1, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Proxy statement: Proxy Filing

May 31, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

May 22, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

ABVC BioPharma Registration statement: Registration Filing

May 10, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Registration statement: Registration Filing

Apr 24, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Registration statement: Registration Filing

ABVC BioPharma Proxy statement: Proxy Filing

Apr 14, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Apr 10, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Apr 6, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

ABVC BioPharma Proxy statement: Proxy Filing

Apr 4, 2023, 8:00 AM EDT - 3 years ago

ABVC BioPharma Proxy statement: Proxy Filing

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Mar 31, 2023, 6:49 PM EDT - 3 years ago

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

Mar 20, 2023, 7:00 AM EDT - 3 years ago

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

Mar 14, 2023, 7:00 AM EDT - 3 years ago

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

ABVC BioPharma Provides 2023 Pipeline Update

Feb 28, 2023, 8:30 AM EST - 3 years ago

ABVC BioPharma Provides 2023 Pipeline Update

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Feb 23, 2023, 4:16 PM EST - 3 years ago

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

Feb 21, 2023, 8:30 AM EST - 3 years ago

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Jan 19, 2023, 8:30 AM EST - 3 years ago

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

Jan 5, 2023, 8:30 AM EST - 3 years ago

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

Nov 17, 2022, 8:30 AM EST - 3 years ago

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

Nov 14, 2022, 6:20 PM EST - 3 years ago

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Nov 7, 2022, 8:30 AM EST - 3 years ago

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

Nov 2, 2022, 8:30 AM EDT - 3 years ago

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

BigdollarMaker
BigdollarMaker Jul. 2 at 7:01 PM
$BB $ABVC Then the rip$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 2 at 1:36 PM
$BB $ABVC When news hits, people don’t even realize how big this is.
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 1 at 8:00 PM
$BB $ABVC Green looks good on you $$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 1 at 5:48 PM
$ABVC $BB busting out
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 1 at 3:12 PM
$BB $ABVC Bring it$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 30 at 7:49 PM
$ABVC $BB More to come, big money incoming$$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 29 at 4:15 PM
$BB $ABVC Cheers$$$ We deserve it!!
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 29 at 3:54 PM
$ABVC $BB To the moon and beyond$$$$
0 · Reply
vcaelum
vcaelum Jun. 25 at 5:20 PM
$ABVC in 1.57 HARD SL 1.4
0 · Reply
BigBoyTroy
BigBoyTroy Jun. 24 at 10:41 PM
$ABVC come join me in free discord link in my stoctwits Profile my bullish 🐂 peeps ABVC levels Support Zones $1.20 – $1.25 → $1.05 – $1.15 → $0.90 – $1.00 → major support $0.70 – $0.80 : Resistance Zones $1.30 – $1.35 $1.45 – $1.55 $1.70 – $1.90 $2.00+
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 24 at 3:26 PM
$BB $ABVC
0 · Reply
specctham
specctham Jun. 17 at 5:11 PM
$ABVC
0 · Reply
OneNightHolder
OneNightHolder Jun. 17 at 12:13 AM
$OTLK $LITS $AKBA $ABVC thes are the holds for tonight. We will check back tomorrow morning.
0 · Reply
XRPisREALmoney
XRPisREALmoney Jun. 16 at 10:33 PM
$LITS $AKBA $OTLK $ABVC these are the overnight holds for today.
0 · Reply
Mmssmm
Mmssmm Jun. 16 at 9:08 AM
$ABVC $ADTX $RDGT $SLBT $TDIC keep dreaming
0 · Reply
TheUnmaker
TheUnmaker Jun. 16 at 9:03 AM
$ADTX very likely $TDIC $SLBT $RDGT $ABVC
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 8 at 4:31 PM
$ABVC When will we get news/earnings?
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 5 at 8:43 PM
$ABVC Great piece that accurately captures ABVC's current position. So if you want to refresh your understanding of ABVC or learn about ABVC for the first time, this is essential reading. https://everyticker.com/quote/ABVC/analysis/abvc-biopharma-a-pre-revenue-option-on-pipeline-conversion-racing-against-a-liquidity-clock-nasdaq-abvc
0 · Reply
topstockalerts
topstockalerts Jun. 5 at 12:47 AM
$ABVC the chart is starting to tell a story
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 4 at 5:10 PM
$ABVC $BB Go time$$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 3 at 3:05 PM
$BB $ABVC Something big is on the way$$$$$MONEY
0 · Reply
BigdollarMaker
BigdollarMaker Jun. 3 at 1:56 PM
$ABVC
0 · Reply